REMARKS

Claims 1 and 2 have been canceled. Claims 3 and 18 have been place in independent

form including the recitations of claim 1. The claims have also been amended so that they are in

better form without narrowing their scope.

Entry of the above amendment is respectfully requested.

Priority

On the Office Action Summary, the Examiner has neither acknowledged Applicants'

claim for priority nor indicated that a copy of the certified copy of the priority document has

been received from the International Bureau.

Since priority was claimed when the application was filed, and since a copy of the

certified copy of the priority document has been received by the PTO from the International

Bureau, Applicants respectfully request that the Examiner acknowledge Applicants' claim for

priority and indicate that a copy of the certified copy of the priority document has been received

from the International Bureau in the next communication from the PTO.

Anticipation Rejection

Claims 1 and 2 rejected under 35 U.S.C. 102(b) as being anticipated by Beilstein (1988-

2001 Brillstein Institut, cited in IDS).

In response, and to expedite allowance, claims 1 and 2 have been canceled. Accordingly,

this rejection has been obviated, and withdrawal of this rejection is respectfully requested.

31

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/522,523

Attorney Docket No.: 085512

Objection to Claims 3-47

Claims 3-47 are objected to as being dependent upon a rejected base claim, but would be

allowable if rewritten in independent form including all of the limitations of the base claim and

any intervening claims.

Applicants thank the Examiner for indicating that claims 3-47 would be allowable if

rewritten in independent form including all of the limitations of the base claim and any

intervening claims. In view of the Examiner's indication, Applicants have so rewritten claims 3-

47, and thus withdrawal of this objection is respectfully requested.

Restriction Requirement

Claims 48-67 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as

being drawn to a nonelected claims, there being no allowable generic or linking claim.

Applicants respectfully request that the Examiner reconsider and withdraw the restriction

requirement in view of the following remarks.

Applicants submit that the amended claims specifically define novel diamine side chains.

There is not any anticipation of the diamine side chains with any one of the prior art. Hence,

Applicants submit that a further restriction of the invention would be an unjustified penalty for

the inventors and circumvent them from the benefits from their invention.

Considering the diamine claims 1 to 41, Applicants submit the gist of the invention or the

actual application will always be the final structure, which are the orientation layers, the optical

or electro-optical components. Applicants submit that a diamine according to claims 1 to 41

only makes sense if finally it will be conducted into the end structure. Applicants submit that

there is no use in just providing protection to the side chain compound as such if they are not

32

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/522,523

. a.a.d 100

further processed to an end structure such as a polymer, layer structure and optical or electro-

optical components. Such end structures are defined in claims 42 to 67.

The compound according to claims 1 to 41 is therefore the precursor for such a final

Attorney Docket No.: Q85512

structure as defined in claims 42 to 67. So, the layer, the optical or electro-optical components

are the aim and the logical consequence of the photoreactive dendrimers according to claim 1 to

41.

Hence, Applicants consider that the present invention is uniform, and that all the claims

should be allowed.

Conclusion

In view of the above, reconsideration and allowance of this application are now believed

to be in order, and such actions are hereby solicited. If any points remain in issue which the

Examiner feels may be best resolved through a personal or telephone interview, the Examiner is

kindly requested to contact the undersigned at the telephone number listed below.

The USPTO is directed and authorized to charge all required fees, except for the Issue

Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any

overpayments to said Deposit Account.

Respectfully submitted,

Registration No. 33,725

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: September 17, 2007

33